



#### **CCP5 Summer School**

July 2023


Simulations of biomolecules: design of small molecule complement C5 inhibitors

DR. AGNIESZKA K. BRONOWSKA

SCHOOL OF NATURAL ENVIRONMENTAL SCIENCES


NEWCASTLE UNIVERSITY

# CADD pipeline



# Molecular docking

The process of predicting the stable 3D geometry of an interacting pair of molecules - a *binding mode/pose* Energy-based docking relies on molecular mechanical force fields (energy minimisation, sampling, scoring function)



# Molecular docking: two main tasks

 Sampling of ligand conformational space and pose generation (geometry)

Scoring protein-ligand complexes (energetics)

# Molecular docking: to-do list

Problem: a pair of molecules represented by their 3D coordinates


- Decide whether the molecules will form a complex;
- Determine the binding affinity (free binding energy);
- Predict the 3D structure of the complex (binding mode);
- •Deduce function (agonist/antagonist);

# SeeSAR

#### SeeSAR

- Platform-independent
- •Easy to use (for basic functionalities) developed for bench chemists
- Decent scoring function (interactions + solvation term used)
- Minimum prep and requirement for e.g. format parsing
- •Rapid core expansion, core replacement and analogue search enabled
- Handles multiple file formats
- Covalent docking enabled
- Integrated with other tools, e.g. InfiniSee (chemical space search), RDKit, KNIME

# HYDE scoring function: the concept



$$\Delta G^{i}_{HYDE} = \sum_{atom \ i} \Delta G^{i}_{dehydration} + \Delta G^{i}_{H-bond}$$


### HYDE – visual affinities

08

-∆G contribution

no ΔG contribution





total desolvation gain	<u>-7.2</u> kJ/mol
ligand aromatic carbon	-2.0 kJ/mol
receptor aromatic carbons	-5.2 kJ/mol




# SeeSAR: a working example

Ligand moves (optimisation after every modification), protein fixed: single conformation

Exhaustive conformational search on ligands prior to docking

Scoring function (HYDE) gives contributions from intrinsic interactions and desolvation



MCC950 bound to NLRP3 inflammasome

Predicted affinity range: High pM to low nM

Ki (SPR and MST): Low nM (8 – 24 nM)

### Limitations and some known issues

- •Protein is considered rigid: ideally, you should follow your calculations by running short MD simulations on the complexes and recalculating the binding affinities
- •Results are very sensitive to even small changes in the conformation of the protein
- •Binding affinities for certain groups are not reproduced well: hydrophobic effect tends to be overestimated, while highly polar groups are underestimated
- •Every now and then, weird protonation states suggested (you can always manually adjust) and med-chem nonsense molecules suggested in core expansion in Inspirator
- Workflows are limited to small molecules
- Med-chem properties and/or synthetic feasibility of suggested analogues may be problematic
- •Technical: 50,000 compounds/rows in SeeSAR GUI (you need to use KNIME to "downsize" very large data sets, or use non-GUI version)

# Virtual Screening

# Virtual screening using SeeSAR and InfiniSee

- •Docking of a large virtual libraries (1,000+) of compounds
- •Libraries: collections of small molecules for virtual screening
- •Sources: open-access (e.g. ZINC, ChEMBL) or commercial (e.g. Enamine) virtual libraries
- •Types of libraries commonly used: fragments, diversity sets, target-focused, custom

## Fragment libraries: Enamine

#### **Fragment Collection**

MiniFrag Library

sp<sup>3</sup> Rich Fragments

Single Pharmacophore

Carboxylic Acid Fragments

Fluorinated Fragments

#### **Covalent Fragments**

Warhead Subsets

**Cysteine focused Covalent Fragments** 

Serine focused Covalent Fragments

Lysine focused Covalent Fragments

Acrylamides

# **Enamine Essential Fragment Library**

- •320 fragments
- Universal tool for initial screen of novel targets
- Designed in collaboration with research group at University of Cambridge
- All fragments have been tested for water solubility and chemical stability in buffer solution
- Increased hit probability: the structures are based on frequently reported fragment hits and scaffolds derived from experimentally determined structures of protein-ligand complexes

# Diversity libraries

#### **DIVERSITY LIBRARIES**

10 240 compounds

50 240 compounds

Hit Locator Library

Phenotypic Screening Library

Covalent Screening Library

### **Discovery Diversity Set**


High-quality diverse library of latest compounds


10 240 compounds

# Target-focused virtual libraries

#### Kinase libraries:

- Hinge binders (18,000 molecules)
- Aurora A targeted set (2,600 molecules)
- Synthetically feasible
- Comply with drug-like rules
- Evaluated in vitro





# Building your own set: InfiniSee



- Developed from REAL Space Navigator;
- REAL: 21 bln make-on-demand compounds;
- The current version (Artemis) has a choice of several massive libraries (REAL, CHEMriya, GalaXi, eXplore, KnowledgeSpace)

# Size matters: screening ultra-large libraries

#### Ultra-large library docking for discovering new chemotypes


Jiankun Lyu<sup>1,2,10</sup>, Sheng Wang<sup>1,2,10</sup>, Trent E. Balius<sup>2,10</sup>, Isha Singh<sup>1,20</sup>, Anat Levit<sup>2</sup>, Yurii S. Moroz<sup>2,4</sup>, Matthew J. O'Meara<sup>1</sup>, Tao Che<sup>4</sup>, Enkhiangal Algaa<sup>1</sup>, Kateryna Tolmachova<sup>2</sup>, Andrey A. Tolmachova<sup>2</sup>, Brian K. Shoicheti\*, Bryan L. Roth<sup>4,8,8</sup> & John J. Irwin<sup>1,4</sup>

Nature. 2019; 566(7743): 224-229.



RESEARCH HIGHLIGHT | 05 January 2022

Synthesis-on-demand compounds were chosen from 12 different docking score bins (cyan)




A group of new (no precedent) AmpC inhibitors has been identified




# Screening ultra-large virtual libraries


Message: we should aim to explore as much of the chemical space as possible

## Screening of large chemical spaces: "crystals first"




**Start:** 4 PKA-fragment complexes (X-ray)





- Template-based docking using Enamine REAL space (20 bn)
- •93 molecules out of 106 selected compounds synthesized
- •40 compounds were active in at least one validation assay
- Most active follow-up having a 13,500-fold gain in affinity


Crystal structures for 6 of the most promising binders were obtained, verifying the predicted binding modes




# The "combinatorial challenge"

- •Enumerating the GSK space would take 400 Yottabytes (400,00000000000 GB)
- •Estimated to take ~11 trillion years to download using high-power broadband
- Storage of all products of a library of such size is unfeasible
- Way out: storing building blocks and reaction rules allowing on-fly generation of products

Virtual library	Size
GalaXi	10 <sup>9</sup>
Enamine REAL	10 <sup>10</sup>
eXplore	10 <sup>12</sup>
BiosolveIT KnowledgeSpace	10 <sup>14</sup>
GSK XXL	10 <sup>26</sup>




# Three-stage workflow for ulvHTS




# Case Study

COMPLEMENT C5

# Complement pathway and C5




# Complement C5 inhibitors: MoA




**PDB: 3CU7** 

Ensemble (apo)



PDB: 8AYH

# Complement C5 inhibitors



CryoEM structure (3.35 Å resolution) of human complement C5 in complex with small molecule inhibitor (H1H) and CVF  $IC_{50}$ : 0.1 - 5 nM, from 3 assays

H1H

PDB: 8AYH

# Complement C5 inhibitors

a) b) 
$$IC_{50} = 0.44 \,\mu\text{M}$$
  $IC_{50} = 0.21 \,\mu\text{M}$   $IC_{50} = 0.21 \,\mu\text{M}$   $IC_{50} = 0.62 \,\mu\text{M}$   $IC_{50} = 0.11 \,\mu\text{M}$   $IC_{50} > 100 \,\mu\text{M}$ 

## Contents of practical sessions

- Introduction to SeeSAR
- Application 1: lead optimisation
- Application 2: core expansion
- Application 3: core replacement/scaffold-hopping
- Application 4: fast generation and evaluation of analogues
- Application 5: Virtual screening of massive virtual libraries with InfiniSee (Scaffold Hopper) and SeeSAR

### Credits

Shangze Xu Kate Madden

Amelia Stennett Adam Wollman

Junya Zhang Wyatt Yue

Ayaz Ahmad Ehmke Pohl (Durham)

Dominic Alderson João de Souza (RxCelerate)

Jon Heal (RxCelerate)

Christian Lemmen (BiosolvelT)









